Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 4, 2025, the company has repurchased a total of 1,932,484 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily providing pathology services. The company focuses on delivering comprehensive laboratory testing and diagnostic services across Australia.
Average Trading Volume: 789,771
Technical Sentiment Signal: Buy
Current Market Cap: A$554.5M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.